Radioligand Therapy for Prostate Cancer – A Clinical Consultation Guide
European Urology Focus · 2026-10 · 12 (5) · 844-846
DOI: 10.1016/j.euf.2026.06.014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Urology Focus, 2026-10. Verfasst von David Hennes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Austin Health, Melbourne, Australia; Monash University, Hudson Institute of Medical Research, Melbourne, Australia. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Prostatic Neoplasms, Castration-Resistant, Dipeptides, Prostatic Neoplasms. Die Arbeit nennt 13 Literaturangaben. Gefördert von: Prostate Cancer Foundation, Peter MacCallum Foundation.
Abstract (Originalsprache)
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is now an established treatment for metastatic castration-resistant prostate cancer (mCRPC), demonstrating improved oncologic outcomes and incorporation into international guidelines. Landmark trials including VISION, TheraP, and PSMAfore have defined the efficacy, safety, and clinical role of [177Lu] Lu-PSMA-617, showing improvements in survival, progression-free survival, and biochemical response rates. Appropriate patient selection remains critical, relying on PSMA positron emission tomography imaging, disease burden assessment, and multidisciplinary evaluation. Emerging imaging biomarkers may further refine selection but remain investigational. Beyond heavily pretreated mCRPC, evidence is expanding for earlier use in taxane-naïve disease, metastatic hormone-sensitive prostate cancer, and neoadjuvant settings. This Clinical Consultation Guide summarises contemporary evidence, practical treatment considerations, toxicity monitoring, and future directions for integrating PSMA-RLT into prostate cancer management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Austin Health, Melbourne, Australia; Monash University, Hudson Institute of Medical Research, Melbourne, Australia.
- Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Department of Surgery, Austin Health, Melbourne, Australia.
- Department of Urology, Austin Health, Melbourne, Australia.
- Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Department of Surgery, Royal Melbourne Hospital, Melbourne, Australia; EJ Whitten Prostate Cancer Research Centre…
- Department of Urology, Austin Health, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Department of Surgery, Austin Health, Melbourne, Aust…
- Department of Urology, Austin Health, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne…
Förderung
- Prostate Cancer Foundation
- Peter MacCallum Foundation
Zitieren
APA
Hennes, D., Al-Khanaty, A., Monna, M., Lawrentschuk, N., Perera, M. L., Eapen, R. S., Buteau, J. P., Hofman, M. S., & Murphy, D. G. (2026). Radioligand Therapy for Prostate Cancer – A Clinical Consultation Guide. European Urology Focus, 12(5), 844-846. https://doi.org/10.1016/j.euf.2026.06.014
Vancouver
Hennes D, Al-Khanaty A, Monna M, Lawrentschuk N, Perera ML, Eapen RS, et al. Radioligand Therapy for Prostate Cancer – A Clinical Consultation Guide. European Urology Focus. 2026;12(5):844-846. doi:10.1016/j.euf.2026.06.014
BibTeX
@article{Hennes2026,
author = {Hennes, David and Al-Khanaty, Abdullah and Monna, Mylestone and Lawrentschuk, Nathan and Perera, Marlon L and Eapen, Renu S and Buteau, James P and Hofman, Michael S and Murphy, Declan G},
title = {Radioligand Therapy for Prostate Cancer – A Clinical Consultation Guide},
journal = {European Urology Focus},
year = {2026},
volume = {12},
number = {5},
pages = {844--846},
doi = {10.1016/j.euf.2026.06.014}
}
EUVIMED